SOHO 2023 | Considerations for risk-adapted therapy in lower-risk MDS
Robert Hasserjian, MD, Massachusetts General Hospital, Boston, MA, discusses the selection of patients with lower-risk myelodysplastic syndromes (LR-MDS) based on genetics and the Molecular International Prognostic Scoring System (IPSS-M), for a risk-adapted therapy approach. Dr Hasserjian comments on the prevalence of SF3B1 mutation in a large proportion of patients with LR-MDS, and further addresses the importance of using prognostic tools such as the IPSS-M to define the risk of MDS in patients with wild-type SF3B1. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
